AP214/ZP1480

  • 2010

    8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...

    Read More >

  • Meet us

    The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...

    Read More >

AP214/ZP1480

ZP1480 (AP214) is a first-in-class, SIP®-modified peptide targeting melanocortin receptors for the treatment of cardiovascular diseases associated with ischemia and inflammation.

A214/ZP1480 has shown strong effects in disease models to treat and prevent inflammation and organ damage in conditions such as post surgical organ dysfunction. The compound was licensed to Action Pharma on a global basis April 2003.

AP214/ZP1480 has completed clinical Phase I studies where positive surrogate markers have been obtained. A clinical Phase II trial has been launched in the USA in 2008 focusing on renal protection in connection with major surgery for life-threatening cardiovascular diseases. Clinical Phase IIb results are expected H2 2010.

AP214/ZP1480 is targeted at the treatment of patients undergoing cardiac or vascular surgery in risk of post-surgical renal failure. 

To top of page

Tip a friend

Fill in the form below to tip a friend about this page.






Subscribe

When this page is updated you will be updated by e-mail.